Skip to main content
SpringerLink
Log in

Consider augmentation or switching strategies when first-line antidepressants are unsuccessful in major depressive disorder

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Connolly KR, Thase ME. If at first you don’t succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 2011; 71(1): 43–64

    Article  PubMed  CAS  Google Scholar 

  2. Philip NS, Carpenter LL, Tyrka AR, et al. Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era. Expert Opin Pharmacother 2010 Apr; 11(5): 709–22

    Article  PubMed  CAS  Google Scholar 

  3. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006; 354(12): 1231–42

    Article  PubMed  CAS  Google Scholar 

  4. Tranter R, O’Donovan C, Chandarana P, et al. Prevalence and outcome of partial remission in depression. J Psychiatry Neurosci 2002; 27(4): 241–7

    PubMed  Google Scholar 

  5. American Psychiatric Association practice guideline for treatment of patients with major depressive disorder, third edition. Arlington (VA); American Psychiatric Association, 2010 Oct

  6. Institute for Clinical Systems Improvement (ICSI) healthcare guideline: major depression in adults in primary care, thirteenth edition. Bloomington (MN); ICSI, 2010 May

  7. Malhi GS, Adams D, Porter R, et al. Clinical practice recommendations for depression. Acta Psychiatr Scand Suppl 2009; 119(439): 8–26

    Article  Google Scholar 

  8. Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III: pharmacotherapy. J Affect Disord 2009; 117Suppl. 1: S26–43

    Article  PubMed  Google Scholar 

  9. Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression: double-blind, randomised comparison. Br J Psychiatry 1999 Jul; 175: 12–6

    Article  PubMed  CAS  Google Scholar 

  10. Lenox-Smith AJ, Jiang Q. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. Int Clin Psychopharmacol 2008; 23(3): 113–9

    Article  PubMed  Google Scholar 

  11. Baldomero EB, Ubago JG, Cercos CL, et al. Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study. Depress Anxiety 2005; 22(2): 68–76

    Article  PubMed  CAS  Google Scholar 

  12. Thase ME, Kremer C, Rodrigues H. Mirtazapine versus sertraline after SSRI non-response [abstract]. The Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU) of the National Institute of Mental Health; 2001 May 28–31; Phoenix (AZ)

  13. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 2006; 163(7): 1161–72

    Article  PubMed  Google Scholar 

  14. Ferreri M, Lavergne F, Berlin I, et al. Benefits from mianserin augmentation of fluoxetine in patients with major depression non-re-sponders to fluoxetine alone. Acta Psychiatr Scand 2001; 103(1): 66–72

    Article  PubMed  CAS  Google Scholar 

  15. Thase ME, Rush AJ, Howland RH, et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry 2002; 59(3): 233–9

    Article  PubMed  CAS  Google Scholar 

  16. McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 2006 Sep; 163(9): 1531–41

    Article  PubMed  Google Scholar 

  17. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009 Sep; 166(9): 980–91

    Article  PubMed  Google Scholar 

  18. Papakostas GI, Shelton RC. Use of atypical antipsychotics for treatment-resistant major depressive disorder. Curr Psychiatry Rep 2008; 10(6): 481–6

    Article  PubMed  Google Scholar 

  19. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68(6): 843–53

    Article  PubMed  CAS  Google Scholar 

  20. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008; 28(2): 156–65

    Article  PubMed  CAS  Google Scholar 

  21. Berman RM, Fava M, Thase ME, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009; 14(4): 197–206

    PubMed  Google Scholar 

  22. Thase ME, Corya SA, Osuntokun O, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 2007; 68(2): 224–36

    Article  PubMed  CAS  Google Scholar 

  23. Bauer M, Pretorius HW, Constant EL, et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 2009; 70(4): 540–9

    Article  PubMed  CAS  Google Scholar 

  24. El-Khalili N, Joyce M, Atkinson S, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2010; 13(7): 917–32

    Article  PubMed  CAS  Google Scholar 

  25. Mahmoud RA, Pandina GJ, Turkoz I, et al. Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med 2007; 147(9): 593–602

    PubMed  Google Scholar 

  26. Keitner GI, Garlow SJ, Ryan CE, et al. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res 2009; 43(3): 205–14

    Article  PubMed  Google Scholar 

  27. Rapaport MH, Gharabawi GM, Canuso CM, et al. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 2006; 31(11): 2505–13

    Article  PubMed  CAS  Google Scholar 

  28. Goodwin G, Fleischhacker W, Arango C, et al. Advantages and disadvantages of combination treatment with antipsychotics ECNP consensus meeting, March 2008, Nice. Eur Neuropsychopharmacol 2009; 19(7): 520–32

    Article  PubMed  CAS  Google Scholar 

  29. Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 2007; 68(6): 935–40

    Article  PubMed  CAS  Google Scholar 

  30. Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T3 augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry2006; 163(9): 1519–30

    Article  PubMed  Google Scholar 

  31. Altshuler LL, Bauer M, Frye MA, et al. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry 2001; 158(10): 1617–22

    Article  PubMed  CAS  Google Scholar 

  32. Aronson R, Offman HJ, Joffe RT, et al. Triiodothyronine augmentation in the treatment of refractory depression: a meta-analysis. Arch Gen Psychiatry 1996; 53(9): 842–8

    Article  PubMed  CAS  Google Scholar 

  33. Joffe RT, Sokolov ST, Levitt AJ. Lithium and triiodothyronine augmentation of antidepressants. Can J Psychiatry 2006; 51(12): 791–3

    PubMed  Google Scholar 

  34. Candy M, Jones L, Williams R, et al. Psychostimulants for depression. Cochrane Database Syst Rev 2008; (2): CD006722

  35. Fava M, Thase ME, DeBattista C, et al. Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. Ann Clin Psychiatry 2007; 19(3): 153–9

    Article  PubMed  Google Scholar 

  36. Portella MJ, de Diego-Adeliño J, Ballesteros J, et al. Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression. J Clin Psychiatry 2011; 72(7): 962–9

    Article  PubMed  Google Scholar 

  37. Whale R, Terao T, Cowen P, et al. Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: a systematic review. J Psychopharmacol 2010 Apr; 24(4): 513–20

    Article  PubMed  CAS  Google Scholar 

  38. Rush AJ, Trivedi MH, Stewart JW, et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 2011; 168(7): 689–701

    Article  PubMed  Google Scholar 

  39. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 2002; 51(2): 183–8

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Consider augmentation or switching strategies when first-line antidepressants are unsuccessful in major depressive disorder. Drugs Ther. Perspect 27, 7–12 (2011). https://doi.org/10.2165/11207880-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11207880-000000000-00000

Search

Navigation